Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 27;7(7):CD011581.
doi: 10.1002/14651858.CD011581.pub3.

Treatment for chronic methicillin-sensitive Staphylococcus aureus pulmonary infection in people with cystic fibrosis

Molla Imaduddin Ahmed  1 , Saptarshi Mukherjee
Affiliations

Treatment for chronic methicillin-sensitive Staphylococcus aureus pulmonary infection in people with cystic fibrosis

Molla Imaduddin Ahmed et al. Cochrane Database Syst Rev. .

Abstract

Background: Cystic fibrosis is an inherited life-threatening multisystem disorder with lung disease characterized by abnormally thick airway secretions and persistent bacterial infection. Chronic, progressive lung disease is the most important cause of morbidity and mortality in the condition and is therefore the main focus of clinical care and research. Staphylococcus aureus is a major cause of chest infection in people with cystic fibrosis. Early onset, as well as chronic, lung infection with this organism in young children and adults results in worsening lung function, poorer nutrition and increases the airway inflammatory response, thus leading to a poor overall clinical outcome. There are currently no evidence-based guidelines for chronic suppressive therapy for Staphylococcus aureus infection in cystic fibrosis such as those used for Pseudomonas aeruginosa infection. This is an update of a previously published review.

Objectives: To assess the evidence regarding the effectiveness of long-term antibiotic treatment regimens for chronic infection with methicillin-sensitive Staphylococcus aureus (MSSA) infection in people with cystic fibrosis and to determine whether this leads to improved clinical and microbiological outcomes.

Search methods: Trials were identified by searching the Cochrane Cystic Fibrosis and Genetic Disorders Group's Cystic Fibrosis Trials Register, MEDLINE, Embase, handsearching article reference lists and through contact with local and international experts in the field. Date of the last search of the Group's Cystic Fibrosis Trials Register: 09 February 2018.We also searched ongoing trials databases. Date of latest search: 20 May 2018.

Selection criteria: Randomised or quasi-randomised controlled trials comparing any combinations of topical, inhaled, oral or intravenous antimicrobials used as suppressive therapy for chronic infection with methicillin-sensitive Staphylococcus aureus compared with placebo or no treatment.

Data collection and analysis: The authors independently assessed all search results for eligibility. No eligible trials were identified.

Main results: The searches identified 58 trials, but none were eligible for inclusion in the current version of this review.

Authors' conclusions: No randomised controlled trials were identified which met the inclusion criteria for this review. Although methicillin-sensitive Staphylococcus aureus is an important and common cause of lung infection in people with cystic fibrosis, there is no agreement on how best to treat long-term infection. The review highlights the need to organise well-designed trials that can provide evidence to support the best management strategy for chronic methicillin-sensitive Staphylococcus aureus infection in people with cystic fibrosis.

PubMed Disclaimer

Conflict of interest statement

Molla Imaduddin Ahmed declares no known potential conflict of interest.

Saptarshi Mukherjee declares no known potential conflict of interest.

Figures

1
1
PRISMA Study flow diagram.
See this image and copyright information in PMC

Update of

References

References to studies excluded from this review

Adeboyeku 2001 {published data only}
    1. Adeboyeku DU, Agent P, Jackson V, Hodson M. A double blind randomised study to compare the safety and tolerance of differing concentrations of nebulised colistin administered using HaloLite in cystic fibrosis (CF) patients [abstract]. Pediatric Pulmonology 2001;Suppl 22:288. [CENTRAL: 362164; CFGD Register: PI165 ; CRS: 5500100000001976]
Amelina 2000 {published data only}
    1. Amelina E, Senkevich N, Cherniak A, Cherniaev A, Chuchalin A. Home intravenous therapy in adult cystic fibrosis patients. The impact on lung fuction and quality of life [abstract]. European Respiratory Journal 2000;16(Suppl 31):123s. [CENTRAL: 415175; CFGD Register: PI181 ; CRS: 5500100000002262]
App 2000 {published data only}
    1. App EM, Huls G, Bittner‐Dersch P, Stolz S, Lindemann H, Matthys H. Impared lung function influences the serum concentration of inhaled drugs in cystic fibrosis [abstract]. Pediatric Pulmonology 2000;Suppl 20:279‐80. [CENTRAL: 315347; CFGD Register: PI156b ; CRS: 5500100000001731]
    1. Huls G, App EM, Bittner‐Dersch P, Stolz S, Lindemann H. Impaired lung function influences the serum concentration of inhaled drugs in cystic fibrosis [abstract]. 13th International Cystic Fibrosis Congress; 2000 June 4‐8; Stockholm, Sweden. 2000:177. [CENTRAL: 302957; CFGD Register: PI156a ; CRS: 5500100000001691]
Autry 2016 {published data only}
    1. Autry EB, Rybak JM, Leung NR, Gardner BM, Burgess DR, Anstead MI, et al. Pharmacokinetic and pharmacodynamic analyses of ceftaroline in adults with cystic fibrosis. Pharmacotherapy 2016;36(1):13‐8. - PubMed
Carswell 1987 {published data only}
    1. Carswell F, Ward C, Cook DA, Speller DC. A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the outpatient management of children with cystic fibrosis. British Journal of Diseases of the Chest 1987;81(4):356‐60. [CENTRAL: 53621; CFGD Register: PI54 ; CRS: 5500100000000343; PUBMED: 3329531] - PubMed
Chua 1990 {published data only}
    1. Chua H, Collis G, Souef P. Bronchial response of children with cystic fibrosis to nebulised antibiotics [abstract]. Australian and New Zealand Journal of Medicine 1990;20:537. [CENTRAL: 320152; CFGD Register: PI66b ; CRS: 5500100000001769]
    1. Chua HL, Collis GG, Souef PN. Bronchial response to nebulized antibiotics in children with cystic fibrosis. European Respiratory Journal 1990;3(10):1114‐6. [CENTRAL: 74980; CFGD Register: PI66a ; CRS: 5500100000000468; PUBMED: 2090472] - PubMed
Coates 2011 {published data only}
    1. Coates AL, Denk O, Leung K, Ribeiro N, Chan J, Green M, et al. Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis. Pediatric Pulmonology 2011;46(4):401‐8. [CENTRAL: 786190; CFGD Register: PI241b ; CRS: 5500100000006333] - PubMed
    1. Denk O, Coates AL, Keller M, Leung K, Green M, Chan J, et al. Lung delivery of a new tobramycin nebuliser solution (150mg/1.5ml) by an investigational eFlow® nebuliser is equivalent to TOBI® but in a fraction of time [abstract]. Journal of Cystic Fibrosis 2009;8 Suppl 2:S66, Abstract no: 264. [CENTRAL: 794467; CFGD Register: PI241c ; CRS: 5500100000003576]
    1. Keller M, Coates AL, Griese M, Denk O, Schierholz J, Knoch M. In‐vivo data support equivalent therapeutic efficacy of a new tobramycin inhalation solution (150mg/1.5ml) administered by the eFlow® electronic nebuliser compared to TOBI® in the PARI LC PLUS® [abstract]. Journal of Cystic Fibrosis 2010;9 Suppl 1:S22, Abstract no: 84. [CENTRAL: 794286; CFGD Register: PI241a ; CRS: 5500100000003569]
Conway 1996 {published data only}
    1. Conway SP. Ceftazidime 3G BD is as effective as ceftazidime 2G TDS in the treatment of respiratory exacerbations in cystic fibrosis [abstract]. Israel Journal of Medical Sciences 1996;32(Suppl):S256. [CENTRAL: 291256; CFGD Register: PI78 ; CRS: 5500100000001321]
Cooper 1985 {published data only}
    1. Cooper DM, Harris M, Mitchell I. Comparison of intravenous and inhalation antibiotic therapy in acute pulmonary deterioration in cystic fibrosis [abstract]. American Review of Respiratory Disease 1985;131:A242. [CENTRAL: 208500; CFGD Register: PI129 ; CRS: 5500100000001084]
Dalbøge 2013 {published data only}
    1. Dalbøge CS, Pressler T, Høiby N, Nielsen KG, Johansen HK. A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF. Journal of Cystic Fibrosis 2013;12(1):42‐8. [DOI: 10.1016/j.jcf.2012.06.005] - DOI - PubMed
Dasenbrook 2015 {published data only}
    1. Dasenbrook EC. Emerging therapies in cystic fibrosis: aerovanc for the treatment of chronic MRSA [abstract]. Pediatric Pulmonology 2015;50 Suppl 41:149, Abstract no: S11.4. [CENTRAL: 1092196; CFGD Register: PI289a; CRS: 5500135000001385]
    1. Marich C, Lord J, Dasenbrook EC, Flume PA, Jouhikainen T. Pharmacokinetics of vancomycin in plasma and sputum following pulmonary administration in cystic fibrosis patients with persistent methicillin‐resistant staphylococcus aureus infection. Pediatric Pulmonology 2016;51 Suppl 45:298‐99. [Abstract no.: 282; CFGD Register: PI289b]
Davis 1987 {published data only}
    1. Davis RL, Koup JR, Williams Warren J, Weber A, Heggen L, Stempel D, et al. Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrobial Agents and Chemotherapy 1987;31(6):915‐9. [CENTRAL: 49449; CFGD Register: PI50 ; CRS: 5500100000000303; PUBMED: 3619423] - PMC - PubMed
Davis 1990 {published data only}
    1. Davis S, Davis P, Mather F, Tankersly P, Waring W. A randomized trial of home intravenous antibiotic therapy (HIVAT) in cystic fibrosis (CF) : Short‐term safety and efficacy [abstract]. Pediatric Pulmonology 1990;Suppl 5:245. [CENTRAL: 291272; CFGD Register: PI91a ; CRS: 5500100000001336]
    1. Davis S, Davis P, Mather F, Waring W, Home IVASG. A randomized trial of home intravenous antibiotic therapy (HIVAT) in cystic fibrosis (CF): Short‐term psychological effects [abstract]. Pediatric Pulmonology 1990;Suppl 5:281‐2. [CENTRAL: 291273; CFGD Register: PI91b ; CRS: 5500100000001337]
Degg 1996 {published data only}
    1. Degg C, Mulheran M. The effect of frequent exposure to gentamicin on distortion product OAEs in patients with cystic fibrosis. British Journal of Audiology 1996;30(2):99‐100. [CENTRAL: 385714; CFGD Register: PI167 ; CRS: 5500100000002095]
Dodd 1997 {published data only}
    1. Dodd M, Maddison J, Abbott J, Webb AK. The effect of the tonicity of nebulised colistin on lung function in adults with cystic fibrosis [abstract]. 18th European Cystic Fibrosis Conference; 1993 May 21‐26; Madrid, Spain. 1993:121. [CENTRAL: 291278; CFGD Register: PI100a ; CRS: 5500100000001342]
    1. Dodd ME, Abbott J, Maddison J, Moorcroft AJ, Webb AK. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax 1997;52(7):656‐8. [CENTRAL: 142169; CFGD Register: PI100b; CRS: 5500100000000830; PUBMED: 9246141] - PMC - PubMed
    1. Dodd ME, Maddison J, Abbot J, Webb AR. The effect of the tonicity of nebulised colistin on chest tightness and lung function in adults with cystic fibrosis [abstract]. European Respiratory Journal 1993;6(Suppl 17):515s. [CENTRAL: 393381; CFGD Register: PI100c ; CRS: 5500100000002149]
Dodd 1998 {published data only}
    1. Dodd ME, Haworth CS, Moorcroft AJ, Miles J, Webb AK. Is medicine evidence‐based when there is discrepancy between patient reported and objective measures of compliance in clinical trials? [abstract]. Pediatric Pulmonology 1998;26(Suppl 17):389‐90. [CENTRAL: 291279; CFGD Register: PI237 ; CRS: 5500100000001343]
Geller 2004 {published data only}
    1. Geller DE, Rodriguez CA, Howenstine M, Murphy T, Voter K, Nickerson B, et al. The effects of doubling concentration of tobramycin solution for inhalation on pharmacokinetics (PK), safety and delivery time in patients with cystic fibrosis (CF) [abstract]. American Journal of American Journal of Respiratory and Critical Care Medicine 2004;169(7):A391. [CENTRAL: 486943; CFGD Register: PI183a ; CRS: 5500100000002627]
    1. Rosenfeld M, Geller DE, Rodriguez CA, Howenstine M, Konstan M, Ordonez C, et al. Serum pharmacokinetics of two preparations of tobramycin solution for inhalation in young cystic fibrosis patients [abstract]. American Journal of Respiratory and Critical Care Medicine 2004;169(7):A386. [CENTRAL: 495351; CFGD Register: PI183b ; CRS: 5500100000002644]
Geller 2008 {published data only}
    1. Geller DE, Flume P, Schwab R, Fornos P, Conrad DJ, Morgan E, et al. A phase 1 safety, tolerability and pharmacokinetic (PK) study of MP‐376 (levofloxacin solution for inhalation) in stable cystic fibrosis (CF) patients [abstract]. Pediatric Pulmonology 2008;43 Suppl 31:315, Abstract no: 321. [CENTRAL: 744131; CFGD Register: PI210b; CRS: 5500100000003459]
    1. Griffith DC, Hansen C, Pressler T, Balchen T, Jensen TJ, Geller DE, et al. Single‐dose pharmacokinetics of aerosol MP‐376 (levofloxacin solution for inhalation) in cystic fibrosis patients: PK‐PD implications [abstract]. Journal of Cystic Fibrosis 2008;7(Suppl 2):S26. [CENTRAL: 643120; CFGD Register: PI210a ; CRS: 5500100000003230]
    1. Kearns GL, Rubino CM, Griffith DC, Geller DE, Forrest A, Bhavnani SM, et al. Levofloxacin pharmacokinetics (PK) after administration of MP‐376 (Levofloxacin inhalation solution; Aeroquin) in children with cystic fibrosis [abstract]. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society 2011;10 Suppl 1:S23, Abstract no: 88. [CENTRAL: 1053535; CFGD Register: PI210d; CRS: 5500133000000015]
    1. Stockmann C, Hillyard B, Ampofo K, Spigarelli MG, Sherwin CM. Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis. Expert Review of Respiratory Medicine 2014:1‐10. [CENTRAL: 1053533; CFGD Register: PI210c; CRS: 5500131000000314; JID:: 101278196; PUBMED: 25417708] - PubMed
Geller 2011a {published data only}
    1. Geller DE, Flume PA, Griffith DC, Morgan E, White D, Loutit J, et al. Pharmacokinetics (PK) of aerosol MP‐376 (aeroquin; levofloxacin inhalation solution) in CF patients [abstract]. Journal of Cystic Fibrosis 2010;9 Suppl 1:S23, Abstract no: 87. [CENTRAL: 848915; CFGD Register: PI254a ; CRS: 5500100000010626]
    1. Geller DE, Flume PA, Griffith DC, Morgan E, White D, Loutit JS, et al. Pharmacokinetics and safety of MP‐376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrobial Agents and Chemotherapy 2011;55(6):2636‐40. [CENTRAL: 801007; CFGD Register: PI254b ; CRS: 5500100000010627] - PMC - PubMed
Geller 2011b {published data only}
    1. Conrad D, Flume P, Sindel L, Andrews S, Morgan L, Loutit J, et al. Phase 2b study of inhaled MP‐376 (Aeroquin, levofloxacin inhalation solution) in stable cystic fibrosis (CF) patients with chronic Pseudomonas Aeruginosa (PA) lung infection. American Journal of Respiratory and Critical Care Medicine 2010;181(Meeting Abstracts). [CFGD Register: PI240g]
    1. Flume P, Geller DE, Sindel L, Staab D, Fischer R, Riethmuller J, et al. Effects of inhaled MP‐376 (aeroquin, levofloxacin inhalation solution) on lung function in stable cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (PA) lung infection [abstract]. Journal of Cystic Fibrosis 2010;9 Suppl 1:S23, Abstract no:86. [CENTRAL: 774683; CFGD Register: PI240a ; CRS: 5500100000003504]
    1. Flume P, VanDevanter DR, Cohen F, Fleming R, Elborn JS. Safety profile of levofloxacin inhalation solution from 3 controlled cystic fibrosis trials [abstract]. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society 2015;14 Suppl 1:S87, Abstract no: 117. [CENTRAL: 1077213; CFGD Register: PI240f // PI283c ; CRS: 5500135000001302]
    1. Flume PA, Geller DE, Loutit JS, Dudly MN, Conrad D, Mpex 204S group. Effects of inhaled MP‐376 (Aeroquin™ levofloxacin inhalation solution) on cystic fibrosis patients with both Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA) lung infection [abstract]. Journal of Cystic Fibrosis 2011;10 Suppl 1:S22, Abstract no: 87. [CENTRAL: 849020; CFGD Register: PI240b ; CRS: 5500100000010582]
    1. Geller DE, Flume PA, Staab D, Fischer R, Loutit JS, Conrad DJ. Levofloxacin inhalation solution (MP‐376) in patients with cystic fibrosis with Pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine 2011;183(11):1510‐6. [CENTRAL: 800852; CFGD Register: PI240d ; CRS: 5500100000010625] - PubMed
Goldfarb 1986 {published data only}
    1. Goldfarb J, Wormser GP, Inchiosa MAJ, Guideri G, Diaz M, Gandhi R, et al. Single‐dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. Journal of Clinical Pharmacology 1986;26(3):222‐6. [CENTRAL: 42124; CFGD Register: PI44 ; CRS: 5500100000000255; PUBMED: 2937812] - PubMed
Gulliver 2003 {published data only}
    1. Gulliver T, Wilson S, Williams G, Harris M, Cooper D. Nebulized tobramycin (intravenous solution) is tolerated without inducing cough and wheeze in cystic fibrosis patients [abstract]. Proceedings of the Thoracic Society of Australia & New Zealand Annual Scientific Meeting; 2003 April 4‐9; Adelaide, Australia. 2003:Abstract no: P139. [CENTRAL: 593086; CFGD Register: PI184 ; CRS: 5500100000003041]
Heininger 1993 {published data only}
    1. Heininger U, Bowing B, Stehr K, Solbach W. Aminoglycosides in patients with mucoviscidosis and pulmonary exacerbation. Comparison of once or three times daily administration [Aminoglykoside bei Patienten mit Mukoviszidose und pulmonaler Exazerbation: Vergleich von Einmal‐ und Dreimalgabe]. Klinische Padiatrie 1993;205(1):18‐22. [CENTRAL: 91490; CFGD Register: PI74 ; CRS: 5500100000000564; PUBMED: 8445848] - PubMed
Hjelte 1988 {published data only}
    1. Hjelte L, Widen B, Malmborg AS, Freyschuss U, Strandvik B. [Intravenous administration of antibiotics at home in patients with cystic fibrosis improves quality of life] [Intravenos antibiotikabehandling i hemmet vid cystisk fibros ger okad livskvalitet]. Lakartidningen 1988;85(18):1614‐7. [CENTRAL: 53458; CFGD Register: PI206 ; CRS: 5500100000000341; PUBMED: 3283482] - PubMed
Huang 1979 {published data only}
    1. Huang N, Palmer J, Schidlow D, Hsuan F, Hsu C, Goldberg M, et al. Evaluation of antibiotic therapy in patients with cystic fibrosis [abstract]. Chest 1979;76(3):354‐5. [CENTRAL: 291362; CFGD Register: PI113a ; CRS: 5500100000001409]
    1. Huang NN, Palmer J, Braverman S, Keith HH, Schidlow D. Therapeutic efficacy of ticarcillin and carbenicillin in patients with cystic fibrosis: a double blind study [abstract]. 23rd Annual Meeting Cystic Fibrosis Club Abstracts; 1982 May 14; Washington D.C. 1982:124. [CENTRAL: 291363; CFGD Register: PI113b ; CRS: 5500100000001410]
Junge 2001 {published data only}
    1. Junge S, Kruger K, Schonweiler R, Ptok M, Ballmann M. Once daily dosage of intravenous trobramycin ‐ increased risk for cochlea damage in children with cystic fibrosis (CF)? [abstract]. Pediatric Pulmonology 2001;Suppl 22:291. [CENTRAL: 362190; CFGD Register: PI160b ; CRS: 5500100000001990]
    1. Kruger K, Junge S, Schonweiler R, Ptok M, Ballmann M. Once daily dosage of intravenous trobramycin in patients with cystic fibrosis ‐ increased risk for cochlea damage? [abstract]. 24th European Cystic Fibrosis Conference; 2001 June 6‐9; Vienna, Austria. 2001:P191. [CENTRAL: 354425; CFGD Register: PI160a ; CRS: 5500100000001945]
Kapranov 1995 {published data only}
    1. Kapranov NI, Belousov YB, Kashyrskaya NY, Smirnova EY. Quinoline therapy in children with cystic fibrosis [abstract]. 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:P19. [CENTRAL: 291377; CFGD Register: PI104 ; CRS: 5500100000001422]
Keel 2011 {published data only}
    1. Keel RA, Schaeftlein A, Kloft C, Pope JS, Knauft RF, Muhlebach M, et al. Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Antimicrobial Agents and Chemotherapy 2011;55(7):3393‐8. [CENTRAL: 800442; CFGD Register: PI251 ; CRS: 5500100000005261] - PMC - PubMed
Khorasani 2009 {published data only}
    1. Khorasani EN, Mansouri F. Effect of zinc supplementation on respiratory infections in children with cystic fibrosis. European Respiratory Society Annual Congress; 2009; Sept 12‐16; Vienna, Austria. 2009:722s. [Abstract no.: P4032; CFGD Register: GN255]
Knight 1979 {published data only}
    1. Knight RK, Batten JC, Mearns M. A double blind trial of cephalexin in cystic fibrosis patients with pseudomonas in the sputum [abstract]. 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12‐13; Noordwijkerhout, the Netherlands. 1979:52. [CENTRAL: 291389; CFGD Register: PI124 ; CRS: 5500100000001431]
Kun 1984 {published data only}
    1. Kun P, Landau LI, Phelan PD. Nebulized gentamicin in children and adolescents with cystic fibrosis. Australian Paediatric Journal 1984;20:43‐5. [CENTRAL: 208154; CFGD Register: PI106 ; CRS: 5500100000001047] - PubMed
Kuti 2004 {published data only}
    1. Kuti J, Nightingale C, Knauft R, Nicolau D. Pharmacokinetics (PK) of continuously infused meropenem (MEM) in adults with cystic fibrosis (CF) [abstract]. American Journal of Respiratory and Critical Care Medicine 2003:Poster: B2. [CENTRAL: 431304; CFGD Register: PI174a ; CRS: 5500100000002301]
    1. Kuti JL, Nightingale CH, Knauft RF, Nicolau DP. Pharmacokinetic properties and stability of continuous‐infusion meropenem in adults with cystic fibrosis. Clinical Therapeutics 2004;26(4):493‐501. [CENTRAL: 468644; CFGD Register: PI174b ; CRS: 5500100000002549; PUBMED: 15189746] - PubMed
Labiris 2004 {published data only}
    1. Labiris R, Freitag A, Pratt B, Efthimiadis A, Hargreave F, Dolovich M. Does inhalation of preservatives from IV tobramycin preparations (TOB) cause airway inflammation? [abstract]. American Journal of Respiratory and Critical Care Medicine 2004;169(7):A307. [CENTRAL: 494424; CFGD Register: PI182 ; CRS: 5500100000002643]
Loening ‐Bauke 1979 {published data only}
    1. Loening Baucke VA, Mischler E, Myers MG. A placebo‐controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis. Journal of Pediatrics 1979;95(4):630‐7. [CENTRAL: 21139; CFGD Register: PI19b ; CRS: 5500100000000098; PUBMED: 383934] - PubMed
    1. Loening‐Baucke VA, Mischler EH, Myers MG. Cephalexin in cystic fibrosis: a placebo‐controlled study [abstract]. Pediatric Research 1978;12(4 Pt 2):495. [CENTRAL: 189031; CFGD Register: PI19c ; CRS: 5500100000000980; EMBASE: 1978335753]
    1. Loening‐Bauke V, Mischler EH, Myers MG. Cephalexin compared to placebo in the management of patients with cystic fibrosis [abstract]. 19th Cystic Fibrosis Club Abstracts; 1978. 1978:69. [CENTRAL: 291430; CFGD Register: PI19a ; CRS: 5500100000001461]
Máiz 2009 {published data only}
    1. Máiz L, Lamas A, Fernández‐Olmos A, Suárez L, Cantón R. Unorthodox long‐term aerosolized ampicillin use for methicillin‐susceptible Staphylococcus aureus lung infection in a cystic fibrosis patient. Pediatric Pulmonology 2009;44(5):512‐5. [DOI: 10.1002/ppul.20983] - DOI - PubMed
Máiz 2012 {published data only}
    1. Lamas A, Maiz L, Campo R, Castro M, Gutierrez‐Alonso D, Giron R, et al. Long‐term inhaled ampicillin for the treatment of methicillin‐susceptible Staphylococcus aureus bronchopulmonary infection in cystic fibrosis patients[abstract]. Journal of Cystic Fibrosis 2011;10 Suppl 1:S55.
    1. Máiz L, Campo R, Castro M, Gutiérrez D, Girón R, Cantón Moreno R. Maintenance treatment with inhaled ampicillin in patients with cystic fibrosis and lung infection due to methicillin‐sensitive Staphylococcus aureus. Archivos de Bronconeumologia 2012;48(10):384. [DOI: 10.1016/j.arbr.2012.07.012] - DOI - PubMed
Nathanson 1985 {published data only}
    1. Nathanson I, Cropp GJA, Li P, Neter E. Effectiveness of aerosolized gentamicin in cystic fibrosis (CF) [abstract]. Cystic Fibrosis Club Abstracts; 1985. 1985; Vol. 28:145. [CENTRAL: 291475; CFGD Register: PI130; CRS: 5500100000001502]
NCT00198289 {published data only}
    1. Aurexis® in cystic fibrosis subjects chronically colonized with Staphylococcus aureus in their lungs. clinicaltrials.gov/ct2/show/NCT00198289 (accessed 29 September 2015). [clinicaltrials.gov: NCT00198289]
Pai 2006 {published data only}
    1. Pai MP, Allen SE, Amsden GW. Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate. Journal of Cystic Fibrosis 2006;5(3):153‐7. [CENTRAL: 570220; CFGD Register: PI199 ; CRS: 5500100000002864; EMBASE: 2006340493; PUBMED: 16481224] - PubMed
Popa 2001 {published data only}
    1. Popa I, Pascu C, Popa Z, Pop L. Forced ionization of the indoor air ‐ an additional method in the treatment of the respiratory disease in cystic fibrosis [abstract]. 24th European Cystic Fibrosis Conference; 2001 June 6‐9; Vienna, Austria. 2001:P69. [CENTRAL: 354440; CFGD Register: PI226 ; CRS: 5500100000001952]
Postnikov 2000 {published data only}
    1. Postnikov SS, Semykin SI, Kapranov NI, Perederko LV, Polikarpova SV, Khamidullina KF. Evaluation of tolerance and efficacy of pefloxacin in the treatment and prevention of severe infections in children with mucoviscidosis and aplastic anemia [Otsenka effektivnosti i perenosimosti pefloksatsina pri lechenii i profilaktike tiazhelykh infektsii u detei s mukovistsidozom i aplasticheskoi anemiei]. Antibiotiki i Khimioterapiia [Antibiotics and Chemoterapy] 2000;45(8):25‐30. [CENTRAL: 372408; CFGD Register: PI171 ; CRS: 5500100000002038; PUBMED: 10989721] - PubMed
Postnikov 2001a {published data only}
    1. Postnikov SS, Semykin SJ, Najimov VP. Safety of fluoroquinolones in children [abstract]. 24th European Cystic Fibrosis Conference; 2001 June 6‐9; Vienna, Austria. 2001:P213. [CENTRAL: 354442; CFGD Register: PI162 ; CRS: 5500100000001953]
Postnikov 2001b {published data only}
    1. Postnikov SS, Semiakin SI, Nazhimov VP, Kapranov NI. Comparative yearly growth rate of children with mucoviscidosis treated and not treated with ciprofloxacin:clinicomorphological comparisons [Cravnitel'naiia godovaia skorost' rosta u detei s mukovistsidozom, poluchavshikh i nepolychavshikh tsiprofloksatsin:klinicomorfologicheskie copostavleniia]. Antibiotiki i Khimioterapiia [Antibiotics and Chemoterapy] 2001;46(10):11‐3. [CENTRAL: 404060; CFGD Register: PI169 ; CRS: 5500100000002231] - PubMed
Prayle 2016 {published data only}
    1. Prayle A, Jain K, Watson A, Smyth AR. Are morning doses of intravenous tobramycin less nephrotoxic than evening? Evidence from urinary biomarkers in the critic study. Pediatric Pulmonology 2013;48 Suppl 36:299. [Abstract no.: 261; CENTRAL: 980338; CFGD Register: CO55a; CRS: 5500125000000420]
    1. Prayle AP, Jain K, Touw DJ, Koch BCP, Knox AJ, Watson A, et al. The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison. Journal of Cystic Fibrosis 2016;15(4):510‐7. [CFGD Register: CO55b] - PMC - PubMed
Ramstrom 2000 {published data only}
    1. Ramstrom H, Erwander I, Mared L, Kornfalt R, Seiving B. Pharmaceutical intervention in the care of cystic fibrosis patients. Journal of Clinical Pharmacy and Therapeutics 2000;25(6):427‐34. [CENTRAL: 329927; CFGD Register: PI159 ; CRS: 5500100000001818; PUBMED: 11123496] - PubMed
Roberts 1993 {published data only}
    1. Roberts GW, Nation RL, Jarvinen AO. Measurement of serum tobramycin in the presence of ticarcillin or piperacillin. Australian Journal of Hospital Pharmacy 1992;22(2):152‐4. [CENTRAL: 284020; CFGD Register: PI132b ; CRS: 5500100000001253]
    1. Roberts GW, Nation RL, Jarvinen AO, Martin AJ. An in vivo assessment of the tobramycin/ticarcillin interaction in cystic fibrosis patients. British Journal of Clinical Pharmacology 1993;36(4):372‐5. [CENTRAL: 339167; CFGD Register: PI132a ; CRS: 5500100000001836; PUBMED: 12959319] - PMC - PubMed
Romano 1992 {published data only}
    1. Romano L, Girosi D, Spallone E, Parisi F, Minicucci L, Romano C. The use of ofloxacin in cystic fibrosis patients [Uso dell'ofloxacin nei pazienti con fibrosi cistica]. Minerva Pediatrica 1992;44(3):79‐86. [CENTRAL: 86795; CFGD Register: PI68b ; CRS: 5500100000000544; PUBMED: 1518497] - PubMed
    1. Romano L, Minicucci L, Spallone E, Girosi D, Campelli A, Fabbri A, et al. [Role of home therapy with ofloxacin in patients with cystic fibrosis (CF)] [Ruolo della terapia domiciliare con ofloxacin in pazienti con fibrosi cistica (FC)]. Giornale Italiano di Chemioterapia 1991;38(1‐3):181‐3. [CENTRAL: 109123; CFGD Register: PI68a ; CRS: 5500100000000661; PUBMED: 1365585] - PubMed
Rosenfeld 2006 {published data only}
    1. Rosenfeld M, Emerson J, Uh D, Anderson G, Genatossio A, McNamara S, et al. Does tobramycin accumulate in respiratory secretions with repeated aerosol administration: a pilot study [abstract]. Pediatric Pulmonology 2006;41 Suppl 29:327. [CENTRAL: 593081; CFGD Register: PI203 ; CRS: 5500100000003036]
Sagel 2009 {published data only}
    1. Sagel SD, Monchil L, Parker D, Emmett P, Wagner B, Abman S. Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study [abstract]. Pediatric Pulmonology 2009;44 Suppl 32:299, Abstract no: 251. [CENTRAL: 921940; CFGD Register: OV21 ; CRS: 5500100000011060]
Salh 1992 {published data only}
    1. Salh B, Bilton D, Dodd M, Abbot J, Webb K. A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis. Scandinavian Journal of Infectious Diseases 1992;24(2):215‐8. [CENTRAL: 86010; CFGD Register: PI72 ; CRS: 5500100000000536; PUBMED: 1641599] - PubMed
Sharma 2016 {published data only}
    1. Sharma G, Lodha R, Shastri S, Saini S, Kapil A, Singla M, et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory care 2016;61(1):78‐84. [CFGD Register: GN256] - PubMed
Singh 2013 {published data only}
    1. Singh SB, Shelton AU, Kotek K, Starner TD. A clinically‐embedded trial to evaluate the efficacy of interventions for pre‐pseudomonal pathogens [abstract]. Pediatric Pulmonology 2013;48 Suppl 36:335, Abstract no: 358. [CENTRAL: 999884; CFGD Register: PI274 ; CRS: 5500127000000006]
Smith 1997 {published data only}
    1. Smith A, Weber A, Pandher R, Williams‐Warren J, Cohen ML, Ramsey B. Utilization of salivary concentrations of ciprofloxacin in subjects with cystic fibrosis. Infection 1997;25(2):106‐8. [CENTRAL: 192506; CFGD Register: PI145 ; CRS: 5500100000000991; EMBASE: 1997101357] - PubMed
Stutman 1987 {published data only}
    1. Shalit I, Stutman HR, Marks MI, Chartrand SA, Hilman BC. Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. American Journal of Medicine 1987;82(Suppl 4A):189‐95. [CENTRAL: 47924; CFGD Register: PI48b ; CRS: 5500100000000293; PUBMED: 3555035] - PubMed
    1. Stutman HR, Shalit I, Marks MI, Greenwood R, Chartrand SA, Hilman BC. Pharmacokinetics of two dosage regimens of ciprofloxacin during a two‐week therapeutic trial in patients with cystic fibrosis. American Journal of Medicine 1987;82(Suppl 4A):142‐5. [CENTRAL: 47920; CFGD Register: PI48a ; CRS: 5500100000000290; PUBMED: 3555028] - PubMed
Vitti 1975 {published data only}
    1. Vitti TG, Berg TJ, Pagtakhan RD. The effect of pancreatic enzyme supplement on the intestinal absorption of ampicillin and cloxacillin in children with cystic fibrosis [abstract]. 16th Cystic Fibrosis Club Abstracts; 1975. 1975:56. [CENTRAL: 291631; CFGD Register: PI81 ; CRS: 5500100000001630]
Willekens 2013 {published data only}
    1. Willekens J, Vanderhelst E, Schutter I, Wachter E, Eyns H, Pierard D, et al. Impact of azithromycin maintenance treatment on Staphylococcus aureus prevalence and macrolide resistance: Experience in one centre [abstract]. Pediatric Pulmonology 2013;48 Suppl 36:329, Abstract no: 342.
Wood 1996 {published data only}
    1. Wood PJ, Ioannides Demos LL, Li SC, Williams TJ, Hickey B, Spicer WJ, et al. Minimisation of aminoglycoside toxicity in patients with cystic fibrosis. Thorax 1996;51(4):369‐73. [CENTRAL: 127097; CFGD Register: PI109 ; CRS: 5500100000000761; EMBASE: 1996127618; PUBMED: 8733487] - PMC - PubMed
Yenduri 2013 {published data only}
    1. Yenduri NJ, Luna RA, Moonnumakal SP, Mann MC, Hiatt PW, Smith EO, Oermann CM. A cross‐sectional study of microbiomes and clinical outcomes in cystic fibrosis patients colonized with MRSA vs MSSA [abstract]. Pediatric Pulmonology 2013;48 Suppl 36:324, Abstract no: 328.

Additional references

Accurso 2007
    1. Accurso FJ. Update in cystic fibrosis 2006. American Journal of Respiratory and Critical Care Medicine 2007;175(8):754‐7. [DOI: 10.1164/rccm.200701-160UP] - DOI - PMC - PubMed
CF Foundation 2013
    1. Cystic Fibrosis Foundation. Annual Patient Registry 2013. https://www.cff.org/2013_CFF_Patient_Registry_Annual_Data_Report.pdf.
CF Foundation 2016
    1. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry. 2016 Annual Data Report. www.cff.org/Research/Researcher‐Resources/Patient‐Registry/2016‐Patient‐... 2017.
CF Trust 2016
    1. Cystic Fibrosis Trust. UK Cystic Fibrosis Registry Annual Data Report 2016. www.cysticfibrosis.org.uk/the‐work‐we‐do/uk‐cf‐registry/reporting‐and‐re... 2017.
Cogen 2015
    1. Cogen J, Emerson J, Sanders DB, Ren C, Schechter MS, Gibson RL, et al. Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. Pediatr Pulmonol 2015 Aug;50(8):763‐70. - PMC - PubMed
Deeks 2011
    1. Deeks JJ, Higgins JPT, Altman DG on behalf of the Cochrane Statistical Methods Group. Chapter 9 Analysing data and undertaking meta‐analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Farrell 2008
    1. Farrell PM. The prevalence of cystic fibrosis in the European Union. Journal of Cystic Fibrosis 2008;7(5):450‐3. [DOI: 10.1016/j.jcf.2008.03.007] - DOI - PubMed
Flume 2007
    1. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey‐Courand DB, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Ameican Journal of Respiratory and Critical Care Medicine 2007;176(10):957‐9. - PubMed
Fuchs 1994
    1. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. New England Journal of Medicine 1994;331(10):637‐42. - PubMed
Gangell 2011
    1. Gangell C, Gard S, Douglas T, Park J, Klerk N, Keil T, et al. Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis. Clin Infect Dis 2011 Sep;53(5):425‐32. - PubMed
Gibson 2003
    1. Gibson RL, Burns JL. Pathophysiology and management of pulmonary infections in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2003;168(8):918‐51. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2011a
    1. Higgins JPT, Altman DG, Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Higgins 2011b
    1. Higgins JPT, Deeks JJ, Altman DG on behalf of the Cochrane Statistical Methods Group (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hubert 2018
    1. Hubert D, Dehillotte C, Munck A, David V, Baek J, Mely L, et al. Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp‐CFTR mutation after 1 and 2years of treatment with ivacaftor in a real‐world setting. J Cyst Fibros. 2018 Jan;17(1):89‐95. - PubMed
Kahl 2010
    1. Kahl BC. Impact of Staphylococcus aureus on the pathogenesis of chronic cystic fibrosis lung disease. International Journal of Medical Microbiology 2010;300(8):514‐9. - PubMed
Kuehnert 2006
    1. Kuehnert MJ, Kruszon‐Moran D, Hill HA, McQuillan G, McAllister SK, Fosheim G, et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001‐2002. Journal of Infectious Diseases 2006;193(2):172‐9. - PubMed
Lommatzsch 2009
    1. Lommatzsch ST, Aris R. Genetics of cystic fibrosis. Seminars in Respiratory and Critical Care Medicine 2009;30(5):531‐8. [DOI: 10.1055/s-0029-1238911] - DOI - PubMed
Quittner 2009
    1. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire‐Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135(6):1610‐8. - PMC - PubMed
Ramsey 1999
    1. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. New England Journal of Medicine 1999;340(1):23‐30. - PubMed
Ratjen 2001
    1. Ratjen F, Comes G, Paul K, Posselt HG, Wagner TO, Harms K, et al. Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis. Pediatric Pulmonology 2001;31(1):13. - PubMed
Ratjen 2003
    1. Ratjen F. Cystic fibrosis. Lancet 2003;361(9358):681‐9. - PubMed
Ratjen 2006
    1. Ratjen F. Diagnosing and managing infection in CF. Pediatric Respiratory Reviews 2006;7 Suppl 1:S151‐3. - PubMed
Razvi 2009
    1. Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 2009;136(6):1554‐60. - PubMed
Ridder‐Schaphorn 2007
    1. Ridder‐Schaphorn S, Ratjen F, Dübbers A, Häberle J, Falk S, Küster P, et al. Nasal Staphylococcus aureus carriage is not a risk factor for lower‐airway infection in young cystic fibrosis patients. Journal of Clinical Microbiology 2007;45(9):2979–84. - PMC - PubMed
Sagel 2009a
    1. Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, et al. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. Journal of Pediatrics 2009;154(2):183‐8. [DOI: 10.1016/j.jpeds.2008.08.001] - DOI - PMC - PubMed
Schünemann 2011a
    1. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Presenting results and ‘Summary of findings’ tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Schünemann 2011b
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Smyth 2005
    1. Smyth A. Prophylactic antibiotics in cystic fibrosis: a conviction without evidence?. Pediatric Pulmonology 2005;40(6):471‐6. - PubMed
Smyth 2012
    1. Smyth AR, Walters S. Prophylactic anti‐staphylococcal antibiotics for cystic fibrosis. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD001912.pub2] - DOI - PubMed
Sterne 2011
    1. Sterne JAC, Egger M, Moher D on behalf of the Cochrane Bias Methods Group (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Stutman 2002
    1. Stutman HR, Lieberman JM, Nussbaum E, Marks MI. Antibiotic prophylaxis in infants and young children with cystic fibrosis: A randomised controlled trial. Journal of Pediatrics 2002;140(3):299‐305. - PubMed
Szaff 1982
    1. Szaff M, Hoiby N. Antibiotic treatment of Staphylococcus aureus infection in cystic fibrosis. Acta Paediatrica Scandinavica 1982;71(5):821–6. - PubMed
Thakare 2017
    1. Thakare R, Singh AK, Das S, Vasudevan N, Jachak GR, Reddy DS, et al. Repurposing Ivacaftor for treatment of Staphylococcus aureus infections. Int J Antimicrob Agents 2017 Sep;50(3):389‐392. - PubMed
Wong 2013
    1. Wong JK, Ranganathan SC, Hart E, Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF). Staphylococcus aureus in early cystic fibrosis lung disease. Pediatric Pulmonology 2013;48(12):1151‐9. [DOI: 10.1002/ppul.22863] - DOI - PubMed
Zolin 2015
    1. Zolin A, Orenti A, Naehrlich L, Rens J, Fox A, Iansa P, et al. European Cystic Fibrosis Society Patient Registry Annual Report 2015. www.ecfs.eu/news/ecfs‐patient‐registry‐2015‐annual‐report 2017.

References to other published versions of this review

Ahmed 2016
    1. Ahmed MI, Mukherjee S. Treatment for chronic methicillin‐sensitive Staphylococcus aureus pulmonary infection in people with cystic fibrosis10.1002/14651858.CD011581.pub2. Cochrane Database of Systematic Reviews 2016, Issue 3. [DOI: 10.1002/14651858.CD011581.pub2] - DOI - PubMed

Publication types

MeSH terms